Correction to: Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.

Correction to: Adv Ther (2021) 38:3550–3588 10.1007/s12325-021-01761-3

The original article was published with an error regarding response to vaccination with ozanimod on page 3561 and in Table 4. The correct sentence and Table 4 are given below

Table 4

Studies on effect of DMTs on response to vaccination

DMT	Study groupsa	Vaccine
IFN
IFN beta-1b (Betaseron®) IFN beta-1b (Extavia®) IFN beta-1a SC (Rebif®) IFN beta-1a IM (Avonex®) PegIFN beta-1a (Plegridy®)	IFN beta-1, N = 46	2011/2012 influenza
	IFN, N = 45	2010/2011 and 2011/2012 influenza
	IFN beta, n = 26 HCs, n = 33	2008/2009 and 2009/2010 influenza
	IFN beta-1a, n = 86 No IFN beta-1a, n = 77	2002/2003 influenza
	IFN beta, n = 36 HCs, n = 216 IFN beta, n = 17 HCs, n = 73	2009 swine flu (H1N1) 2010 influenza
	IFN beta-1a/1b, n = 25 HCs, n = 53	2012/2013 influenza
	Nonpegylated IFN, n = 33 DMF, n = 38	TT-containing Pneumococcal polysaccharide Meningococcal
	IFN beta, n = 10	Tick-borne encephalitis
	IFN beta, N = 14	TT
	High titer IFN alpha/beta, mouse model	Influenza
	IFN beta, mouse model	Recombinant vaccinia viruses followed by fowlpox virus recombinants at 2-week intervals
Glatiramer acetates
Copaxone®	Glatiramer acetate, n = 37 HCs, n = 216	2009 swine flu (H1N1)
	Glatiramer acetate, n = 12 HCs, n = 73	2010 influenza
	Glatiramer acetate, n = 23 HCs, n = 53	2012/2013 influenza
	Glatiramer acetate, n = 26	2010/2011 and 2011/2012 influenza
	Glatiramer acetate, n = 5	Tick-borne encephalitis
DHODH inhibitor
Teriflunomide	Teriflunomide, 7 mg, n = 41 14 mg, n = 41	2011/2012 influenza
	Teriflunomide, n = 23 HCs placebo, n = 23	Rabies
S1P receptor modulators
Fingolimod	Fingolimod, n = 14 HCs, n = 18	2008/2009 and 2009/2010 influenza
	Fingolimod, n = 95 Placebo, n = 43	2010/2011 influenza TT booster (recall antigen)
	Fingolimod, n = 10 IFN beta, n = 10 HCs, n = 15	Influenza
	Fingolimod, n = 6	2010/2011 and 2011/2012 influenza
	Fingolimod, n = 15 HCs, n = 53	2012/2013 influenza
	Fingolimod, n = 11	VZV
	Fingolimod, n = 2	Tick-borne encephalitis
	Fingolimod, n = 48 HCs placebo, n = 24	KLH Pneumococcal polysaccharide (PPV-23) TT
	Fingolimod, 1 patient with MS and childhood history of chicken pox [case report]	VZV
	Fingolimod, 1 patient with MS and chicken pox as a child [case report]	VZV (shingles vaccine 6 months before initiating fingolimod)
	Fingolimod Mouse model	BCG
	Fingolimod Mouse model	Ovalbumin plus CpG oligodeoxynucleotide adjuvant; priming via nasal route
	Fingolimod Mouse model	Influenza A Treated with fingolimod before and during M. tuberculosis challenge
Siponimod	Siponimod, n = 90 across 3 groups of HCs Placebo, n = 30	Pneumococcal polysaccharide (PPV-23) Influenza
Fumarates
Dimethyl fumarate (DMF)	DMF, n = 38 Nonpegylated IFN, n = 33	TT-containing Pneumococcal polysaccharide Meningococcal
High-efficacy DMTs
Anti-VLA4
Natalizumab	Natalizumab, n = 30	TT Neoantigen (KLH)
	Natalizumab, n = 17 HCs, n = 10	Influenza A H1N1/A-H3N2/B)
	Natalizumab, n = 17 HCs, n = 216	2009 swine flu (H1N1)
	Natalizumab, n = 8 HCs, n = 73	2010 influenza (including H1N1, H3N2, and B strains)
	Natalizumab, n = 12 HCs, n = 53	2012/2013 influenza
	Natalizumab, n = 14	2010/2011 and 2011/2012 influenza
Anti-CD20
Ocrelizumab	Ocrelizumab, n = 68 [patients with MS] HCs, n = 34	TT Pneumococcal KLH Influenza
	Patient with MS who received VZV vaccine 4 months before first dose of ocrelizumab [case report], n = 1	VZV
Anti-CD52
Alemtuzumab	Alemtuzumab, n = 24	Pneumococcal polysaccharide Diphtheria, TT, and poliomyelitis HiB and meningococcal group C
DNA synthesis disrupter
Mitoxantrone	Mitoxantrone, n = 11 HCs, n = 216	2009 swine flu
	Mitoxantrone, n = 4 HCs, n = 73	2010 influenza

AE adverse event, BCG Bacillus Calmette–Guérin, DHODH dihydroorotate dehydrogenase, DMF dimethyl fumarate, DMT disease-modifying therapy, HA-hemaglutinin, HC healthy control, HiB Haemophilus influenzae type b, HPV human papillomavirus, IFN interferon, Ig immunoglobulin, IM intramuscular; KLH keyhole limpet hemocyanin, MS multiple sclerosis, PPV pneumococcal polysaccharide vaccine, S1P sphingosine-1-phosphate, SC subcutaneous, TB tuberculosis, TT tetanus toxoid, VZV varicella zoster virus

aUnless indicated otherwise, all study groups are people with MS

H1N1 protection: natalizumab, 75.0%; controls, 71.2%

H3N2 protection: natalizumab, 50.0%; controls, 79.5% [90]

Note: limited sample size and no adjustment for disease factors

Low response rates (14.3% seroprotection, all strains) [87]

Note: small sample size is a limitation of this study

The few data available for other S1P receptor modulators suggest there can be some negative impact on vaccine response (145).